Danaher Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

enVVeno Medical Corp

Change company Symbol lookup

Select an option...

NVNO enVVeno Medical Corp

MTBC CareCloud Inc

WRK Westrock Co

SNDX Syndax Pharmaceuticals Inc

SLAMU Slam Corp

SURYY Sumitomo Realty & Development Co Ltd

MKKGY Merck KGaA

DAC Danaos Corp

YY JOYY Inc

MGU Macquarie Global Infrastructure Total Return Fund Inc.

Health Care : Health Care Equipment & Supplies | Small Cap Growth

Company profile

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Danaher Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains

4:49 pm ET January 10, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Danaher Corp. (DHR) advanced 2.49% to $303.03 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.14% to 4,670.29 and Dow Jones Industrial Average falling 0.45% to 36,068.87. The stock's rise snapped a five-day losing streak. Danaher Corp. closed $30.93 short of its 52-week high ($333.96), which the company reached on September 10th.

The stock underperformed when compared to some of its competitors Monday, as Thermo Fisher Scientific Inc. (TMO) rose 2.96% to $625.04. Trading volume (3.4 M) eclipsed its 50-day average volume of 2.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 10, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 10, 2022 16:49 ET (21:49 GMT)